Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Prognostic impact of TP53 mutation status and variant allele frequency in myelodysplastic syndromes: A meta-analysis of prognosis and transplant outcomes

Daniel Park, Jaden Sanders, Mehak Khattra, Kayla Miles, Aren Dermarderosian, Winston Woan, Eric Tam, George Yaghmour

Blood (2025) 146 (Supplement 1): 7393.

https://doi.org/10.1182/blood-2025-7393

Published: 2025

Journal Articles

Ibrutinib plus blinatumomab in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Results of A phase 2 study

Brian Jonas, Mehrdad Abedi, Aaron Rosenberg, Naseem Esteghamat, Rasmus Hoeg, Lihong Qi, Eric Tam, Joseph Tuscano, George Yaghmour

Blood (2025) 146 (Supplement 1): 3356.

https://doi.org/10.1182/blood-2025-3356

Published: 2025

Journal Articles

CAR t-cell therapy-related cytokine release syndrome and neurotoxicity: Real-world outcomes from a comprehensive cancer center

Allison Hsieh, Amir Ali, Samantha Shi, David Bateshansky, George Yaghmour, Eric Tam, Winston Woan

Blood (2025) 146 (Supplement 1): 7685.

https://doi.org/10.1182/blood-2025-7685

Published: 2025

Journal Articles

Pediatric-inspired USC ALL regimen vs hyper-CVAD in adults with ph-negative ALL: Real-world outcomes including blinatumomab in a predominantly hispanic cohort.

Karam Ashouri, Anush Ginosyan, Sophie Grove, Elaine Huang, Brian Hom, Manali Begur, Tiffany Chen, Grace Kim, Preet Chaudhary, Amir Ali, Imran Siddiqi, Winston Woan, Eric Tam, George Yaghmour

Blood (2025) 146 (Supplement 1): 5132.

https://doi.org/10.1182/blood-2025-5132

Published: 2025

Journal Articles

Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia

Brian Jonas, Sangeetha Venugopal, George Yaghmour, Manu Pandey, Anthony Selwyn Stein, Mikkael Sekeres, Namrata Chandhok, Rasmus Hoeg, Joseph Tuscano, Pamela Becker, Terrence Bradley, Eric Tam, Guido Marcucci, Paul Frankel, Jan Beumer, Steven Gore, Alexey Danilov, Amandeep Salhotra

Blood (2025) 146 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2025-1651

Published: 2025

Journal Articles

Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy

Gabriel Mannis, Nikolai Podoltsev, Deepa Jeyakumar, Justin Watts, Pankit Vachhani, Brian Jonas, Uma Borate, Eric Tam, Harry Erba, Yuling Shi, Donna Haney, William Rice, Rafael Bejar, Naval Daver

Blood (2025) 146 (Supplement 1): 1645.

https://doi.org/10.1182/blood-2025-1645

Published: 2025

Journal Articles

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Blood (2024) 144 (Supplement 1): 4255.

https://doi.org/10.1182/blood-2024-200397

Published: 2024

Journal Articles

Philadelphia-like B-Cell Acute Lymphoblastic Leukemia in a Largely Hispanic Population: Disease Features and Outcomes in the Era of Immunotherapy a Single Institutional Study

Blood (2023) 142 (Supplement 1): 4208.

https://doi.org/10.1182/blood-2023-190716

Published: 2023

Journal Articles

A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation

Blood (2023) 142 (Supplement 1): 5953.

https://doi.org/10.1182/blood-2023-181151

Published: 2023

Journal Articles

Survival and Outcomes after Relapse in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Treated with Venetoclax-Based Chemotherapy

Lydia D Chow, Denaly Chen, Maria E. Vergara-Lluri, Eric Tam, Karrune Woan, Preet M. Chaudhary, George Yaghmour, Abdullah Ladha

Blood (2022) 140 (Supplement 1): 9027–9028.

https://doi.org/10.1182/blood-2022-171127

Published: 2022

Journal Articles

Updated Outcomes in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Using Tyrosine Kinase Inhibitors Combined with the Modified University of Southern California (USC ALL) Regimen without Peg-Asparaginase in the Era of Novel Agents

Vincent Louie Louie Mendiola, Catherine Ly, Jennifer Wang, Thuy Bui, Jack Rodman, Amir Ali, Karrune Woan, Eric Tam, Maria E. Vergara-Lluri, Preet M. Chaudhary, Dan Douer, Abdullah Ladha, George Yaghmour

Blood (2022) 140 (Supplement 1): 11702–11704.

https://doi.org/10.1182/blood-2022-164836

Published: 2022

Journal Articles

Updated Comparison of Outcomes in Hispanic and Non-Hispanic Patients with Ph-Negative Acute Lymphoblastic Leukemia Using the Modified Pediatric-Based University of Southern California Acute Lymphoblastic Leukemia (USC ALL) Regimen in the Era of Novel Agents

Vincent Louie Mendiola, Catherine Ly, Jennifer Wang, Thuy Bui, Jack Rodman, Amir Ali, Karrune Woan, Eric Tam, Maria E. Vergara-Lluri, Preet M. Chaudhary, Dan Douer, Abdullah Ladha, George Yaghmour

Blood (2022) 140 (Supplement 1): 11685–11687.

https://doi.org/10.1182/blood-2022-167684

Published: 2022

Journal Articles

Updated Outcomes of the University of Southern California (USC) ALL Frontline Regimen (based on CCG-1882) after Protocol Modification in the Era of Novel Agents in Ph-Negative ALL Patients

Vincent Louie Ramos Mendiola, Catherine Ly, Jennifer Wang, Thuy Bui, Jack Rodman, Amir Ali, Maria E. Vergara-Lluri, Karrune Woan, Eric Tam, Preet M. Chaudhary, Dan Douer, Abdullah Ladha, George Yaghmour

Blood (2022) 140 (Supplement 1): 11668–11670.

https://doi.org/10.1182/blood-2022-167512

Published: 2022

Journal Articles

Outcomes of Myelofibrosis Patients in the Era of Using JAK2 Inhibitor with Allogeneic-HSCT at the University of Southern California

Vincent Louie Louie Mendiola, Krithika Chennapan, Denaly Chen, Jack Rodman, Amir Ali, Eric Tam, Abdullah Ladha, Karrune Woan, Preet M. Chaudhary, George Yaghmour

Blood (2022) 140 (Supplement 1): 12256–12258.

https://doi.org/10.1182/blood-2022-164745

Published: 2022

Journal Articles

Impact of FLT3 Inhibitor-Based Therapies on Outcomes of Acute Myeloid Leukemia (AML) Patients Receiving Allogenic Stem Cell Transplantation: A Retrospective Study

Krithika Chennapan, Karam Ashouri, Anastasia Martynova, Samvel Nazaretyan, Amir Ali, Eric Tam, Abdullah Ladha, Karrune Woan, Preet M. Chaudhary, Imran Siddiqi, George Yaghmour

Blood (2022) 140 (Supplement 1): 4823–4824.

https://doi.org/10.1182/blood-2022-163658

Published: 2022

Journal Articles

First Reported Evaluation of Outcomes and Safety of Using "Flipped" Conditioning Regimens of Fractionated Total Body Irradiation Followed By Fludarabine Vs Cyclophosphamide for Allogeneic-Hematopoietic Stem Cell Transplant at the University of Southern California

Vincent Louie Louie Mendiola, Denaly Chen, Jack Rodman, Amir Ali, Eric Tam, Abdullah Ladha, Karrune Woan, Preet M. Chaudhary, George Yaghmour

Blood (2022) 140 (Supplement 1): 12821–12823.

https://doi.org/10.1182/blood-2022-164771

Published: 2022

Journal Articles

Updated Outcomes during the Pandemic: Relationship between CD34and CD3 Cell Doses, One-Year Graft-Versus-Relapse-Free-Survival, Graft-Versus-Host Disease, and Overall Survival in Haploidentical Hematopoietic Stem Cell Transplantation Using Post Transplant Cytoxan: A Single Center Experience

Anastasia Martynova, Krithika Chennapan, Jack Rodman, Mindy Hsiao, Abdullah Ladha, Eric Tam, Karrune Woan, Preet M. Chaudhary, George Yaghmour

Blood (2021) 138 (Supplement 1): 1773.

https://doi.org/10.1182/blood-2021-152625

Published: 2021

Journal Articles

Outcomes in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Using Tyrosine Kinase Inhibitors Combined with the Modified University of Southern California (USC ALL) Regimen without Pegaspargase in the Era of Novel Agents; A Retrospective Study

Vincent Louie Ramos Mendiola, Catherine Ly, Thuy Bui, Jennifer Wang, Jack Rodman, Karrune Woan, Eric Tam, Maria E. Vergara-Lluri, Preet M. Chaudhary, Dan Douer, Abdullah Ladha, George Yaghmour

Blood (2021) 138 (Supplement 1): 4372.

https://doi.org/10.1182/blood-2021-150135

Published: 2021

Journal Articles

Evaluating Outcomes Using Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil As Gvhd Prophylaxis Compared with Methotrexate/Tacrolimus in Matched-Related and Matched-Unrelated Hematopoietic Stem Cell Transplant in Relation to the Haploidentical Setting in Acute Lymphoblastic Leukemia: A Single Center Experience

Sami Dwabe, Hugo Martinez, Jack Rodman, Eric Tam, Abdullah Ladha, Karrune Woan, Preet M. Chaudhary, George Yaghmour

Blood (2021) 138 (Supplement 1): 4874.

https://doi.org/10.1182/blood-2021-149165

Published: 2021

Journal Articles

Outcomes of COVID-19 in Hematopoietic Stem-Cell Transplant Recipients: A Single Institution Observational Study

Sami Dwabe, Lakshmi Savitala-Damerla, Jack Rodman, Abdullah Ladha, Eric Tam, Houda Alachkar, Karrune Woan, Preet M. Chaudhary, George Yaghmour

Blood (2021) 138 (Supplement 1): 4896.

https://doi.org/10.1182/blood-2021-149204

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Prognostic impact of TP53 mutation status and variant allele frequency in myelodysplastic syndromes: A meta-analysis of prognosis and transplant outcomes

Ibrutinib plus blinatumomab in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Results of A phase 2 study

CAR t-cell therapy-related cytokine release syndrome and neurotoxicity: Real-world outcomes from a comprehensive cancer center

Pediatric-inspired USC ALL regimen vs hyper-CVAD in adults with ph-negative ALL: Real-world outcomes including blinatumomab in a predominantly hispanic cohort.

Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia

Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy

Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Philadelphia-like B-Cell Acute Lymphoblastic Leukemia in a Largely Hispanic Population: Disease Features and Outcomes in the Era of Immunotherapy a Single Institutional Study

A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation

Survival and Outcomes after Relapse in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Treated with Venetoclax-Based Chemotherapy

Updated Outcomes in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Using Tyrosine Kinase Inhibitors Combined with the Modified University of Southern California (USC ALL) Regimen without Peg-Asparaginase in the Era of Novel Agents

Updated Comparison of Outcomes in Hispanic and Non-Hispanic Patients with Ph-Negative Acute Lymphoblastic Leukemia Using the Modified Pediatric-Based University of Southern California Acute Lymphoblastic Leukemia (USC ALL) Regimen in the Era of Novel Agents

Updated Outcomes of the University of Southern California (USC) ALL Frontline Regimen (based on CCG-1882) after Protocol Modification in the Era of Novel Agents in Ph-Negative ALL Patients

Outcomes of Myelofibrosis Patients in the Era of Using JAK2 Inhibitor with Allogeneic-HSCT at the University of Southern California

Impact of FLT3 Inhibitor-Based Therapies on Outcomes of Acute Myeloid Leukemia (AML) Patients Receiving Allogenic Stem Cell Transplantation: A Retrospective Study

First Reported Evaluation of Outcomes and Safety of Using "Flipped" Conditioning Regimens of Fractionated Total Body Irradiation Followed By Fludarabine Vs Cyclophosphamide for Allogeneic-Hematopoietic Stem Cell Transplant at the University of Southern California

Updated Outcomes during the Pandemic: Relationship between CD34and CD3 Cell Doses, One-Year Graft-Versus-Relapse-Free-Survival, Graft-Versus-Host Disease, and Overall Survival in Haploidentical Hematopoietic Stem Cell Transplantation Using Post Transplant Cytoxan: A Single Center Experience

Outcomes in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Using Tyrosine Kinase Inhibitors Combined with the Modified University of Southern California (USC ALL) Regimen without Pegaspargase in the Era of Novel Agents; A Retrospective Study

Outcomes of COVID-19 in Hematopoietic Stem-Cell Transplant Recipients: A Single Institution Observational Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only